These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Two cases of alprazolam-induced hyperprolactinemia in patients with panic disorder. Shioiri T; Kita N; Takahashi S Int Clin Psychopharmacol; 1996 Jun; 11(2):149-52. PubMed ID: 8803653 [No Abstract] [Full Text] [Related]
30. Decreased plasma cortisol level during alprazolam treatment of panic disorder: a case report. Fukuda M; Takazawa S; Nakagome K; Iwanami A; Hata A; Kasai K; Hiramatsu K Prog Neuropsychopharmacol Biol Psychiatry; 1998 Jul; 22(5):909-15. PubMed ID: 9723127 [TBL] [Abstract][Full Text] [Related]
31. The relationship of alprazolam and clonazepam dose to steady-state concentration in plasma. Labbate LA; Pollack MH; Otto MW; Tesar GM; Rosenbaum JF J Clin Psychopharmacol; 1994 Aug; 14(4):274-6. PubMed ID: 7962684 [TBL] [Abstract][Full Text] [Related]
32. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. Pollack MH; Otto MW; Tesar GE; Cohen LS; Meltzer-Brody S; Rosenbaum JF J Clin Psychopharmacol; 1993 Aug; 13(4):257-63. PubMed ID: 8376613 [TBL] [Abstract][Full Text] [Related]
33. A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder. Rizley R; Kahn RJ; McNair DM; Frankenthaler LM Psychopharmacol Bull; 1986; 22(1):167-72. PubMed ID: 2873609 [No Abstract] [Full Text] [Related]
34. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. Lydiard RB; Ballenger JC; Rickels K J Clin Psychiatry; 1997; 58 Suppl 11():11-8. PubMed ID: 9363043 [TBL] [Abstract][Full Text] [Related]
35. A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety. Bailey JE; Papadopoulos A; Seddon K; Nutt DJ J Psychopharmacol; 2009 Mar; 23(2):117-22. PubMed ID: 18562427 [TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up after a drug trial for panic disorder. Katschnig H; Amering M; Stolk JM; Klerman GL; Ballenger JC; Briggs A; Buller R; Cassano G; Garvey M; Roth M Br J Psychiatry; 1995 Oct; 167(4):487-94. PubMed ID: 8829718 [TBL] [Abstract][Full Text] [Related]
37. A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. Jonas JM; Cohon MS J Clin Psychiatry; 1993 Oct; 54 Suppl():25-45; discussion 46-8. PubMed ID: 8262888 [TBL] [Abstract][Full Text] [Related]
38. [The efficacy of alprazolam in the therapy of panic disorders]. Diukova GM; Vorob'eva OV; Petrova EP; Smirnov SV; Tumalaeva ZN Zh Nevrol Psikhiatr Im S S Korsakova; 1995; 95(4):9-13. PubMed ID: 8533521 [TBL] [Abstract][Full Text] [Related]
39. Generalized anxiety disorder versus panic disorder: participation in controlled efficacy trials. Mavissakalian MR; Zamar N Compr Psychiatry; 2000; 41(4):253-8. PubMed ID: 10929792 [TBL] [Abstract][Full Text] [Related]
40. Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. Bond AJ; Curran HV; Bruce MS; O'Sullivan G; Shine P J Affect Disord; 1995 Dec; 35(3):117-23. PubMed ID: 8749839 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]